---
layout: default
title: Avelumab
description: "Avelumab çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 27
evidence_level: L5
indication_count: 10
---

# Avelumab

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Avelumabï¼šå¾è½‰ç§»æ€§é»˜å…‹ç´°èƒç™Œåˆ°äººé¡çš°ç–¹ç—…æ¯’8ç›¸é—œè…«ç˜¤

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Avelumab å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Avelumab åŸæœ¬ç”¨æ–¼æ²»ç™‚è½‰ç§»æ€§é»˜å…‹ç´°èƒç™Œã€æ™šæœŸè…ç´°èƒç™ŒåŠæ³Œå°¿é“ä¸Šçš®ç™Œçš„ç¶­æŒç™‚æ³•ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**äººé¡çš°ç–¹ç—…æ¯’8ç›¸é—œè…«ç˜¤ (human herpesvirus 8-related tumor)** æœ‰æ•ˆï¼Œä½†ç›®å‰åƒ…æœ‰æ¨¡å‹é æ¸¬æ”¯æŒã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | é©ç”¨æ–¼æ²»ç™‚è½‰ç§»æ€§é»˜å…‹ç´°èƒç™Œ (Merkel Cell Carcinoma)ä¹‹æˆäººç—…äººã€‚ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | human herpesvirus 8-related tumorã€middle ear neuroendocrine tumorã€malignant cutaneous granular cell skin tumorã€ectomesenchymomaã€adenosine deaminase deficiencyã€reticular dysgenesisã€Immunoerythromyeloid hypoplasiaã€non-severe combined immunodeficiencyã€prostatic urethra urothelial carcinomaã€kidney pelvis sarcomatoid transitional cell carcinoma |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.97% |
| è­‰æ“šç­‰ç´š | L5 |
| å°ç£ä¸Šå¸‚ | âœ“ å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 2 å¼µ |
| å»ºè­°æ±ºç­– | Hold |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. human herpesvirus 8-related tumor</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.97%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

<p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ">
ç›®å‰ç¼ºä¹è©³ç´°çš„ä½œç”¨æ©Ÿè½‰è³‡æ–™ã€‚æ ¹æ“šå·²çŸ¥è³‡è¨Šï¼ŒAvelumab æ˜¯ä¸€ç¨® PD-L1 æŠ‘åˆ¶åŠ‘ï¼Œå…¶åœ¨è½‰ç§»æ€§é»˜å…‹ç´°èƒç™Œä¸­çš„ç™‚æ•ˆå·²è¢«è­‰å¯¦ï¼Œæ©Ÿè½‰ä¸Šå¯èƒ½é©ç”¨æ–¼äººé¡çš°ç–¹ç—…æ¯’8ç›¸é—œè…«ç˜¤ã€‚
</p>

<div class="key-takeaway">
æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚
</div>

### è‡¨åºŠè©¦é©—

ç›®å‰ç„¡ç›¸é—œè‡¨åºŠè©¦é©—ç™»è¨˜ã€‚

### ç›¸é—œæ–‡ç»

ç›®å‰ç„¡ç›¸é—œæ–‡ç»ã€‚

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. middle ear neuroendocrine tumor</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.97%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.97%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. malignant cutaneous granular cell skin tumor</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.97%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.97%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. ectomesenchymoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.97%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.97%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. adenosine deaminase deficiency</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.95%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.95%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. reticular dysgenesis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.94%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. Immunoerythromyeloid hypoplasia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.94%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. non-severe combined immunodeficiency</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.92%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.92%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. prostatic urethra urothelial carcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.92%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.92%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. kidney pelvis sarcomatoid transitional cell carcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.91%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨èŒç–«è¼¸å­—ç¬¬001085è™Ÿ | ç™¾ç©©ç›Šæ³¨å°„åŠ‘20æ¯«å…‹/æ¯«å‡ | æ³¨å°„æ¶²åŠ‘ | é©ç”¨æ–¼æ²»ç™‚è½‰ç§»æ€§é»˜å…‹ç´°èƒç™Œ (Merkel Cell Carcinoma)ä¹‹æˆäººç—…äººã€‚ä½µç”¨ axitinib é©ç”¨æ–¼æ™šæœŸè…ç´°èƒç™Œ (Renal Cell Carcinoma, RCC) ç—…äººçš„ç¬¬ä¸€ç·šæ²»ç™‚ã€‚é©ç”¨æ–¼æ¥å—ç¬¬ä¸€ç·šå«é‰‘åŒ–å­¸æ²»ç™‚å¾Œï¼Œç–¾ç—…æœªæƒ¡åŒ–ä¹‹å±€éƒ¨æ™šæœŸæˆ–è½‰ç§»æ€§æ³Œå°¿é“ä¸Šçš®ç™Œ(Urothelial Carcinoma, UC)ç—…äººä¹‹ç¶­æŒç™‚æ³•ã€‚ |

## ç´°èƒæ¯’æ€§

| é …ç›® | å…§å®¹ |
|------|------|
| ç´°èƒæ¯’æ€§åˆ†é¡ | å…ç–«æ²»ç™‚ |
| éª¨é«“æŠ‘åˆ¶é¢¨éšª | è«‹åƒè€ƒåŸå» ä»¿å–®çš„è­¦èªèˆ‡æ³¨æ„äº‹é … |
| è‡´åæ€§åˆ†ç´š | è«‹åƒè€ƒåŸå» ä»¿å–®çš„è­¦èªèˆ‡æ³¨æ„äº‹é … |
| ç›£æ¸¬é …ç›® | è«‹åƒè€ƒåŸå» ä»¿å–®çš„è­¦èªèˆ‡æ³¨æ„äº‹é … |
| è™•ç½®é˜²è­· | è«‹åƒè€ƒåŸå» ä»¿å–®çš„è­¦èªèˆ‡æ³¨æ„äº‹é … |

## å®‰å…¨æ€§è€ƒé‡

- **è—¥ç‰©äº¤äº’ä½œç”¨**ï¼šAvelumab èˆ‡ Lenalidomideã€Pomalidomideã€Thalidomide ä¹‹é–“æœ‰é‡å¤§è—¥ç‰©äº¤äº’ä½œç”¨ã€‚


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Hepatic Insufficiency** ğŸŸ¡ Moderate
- No clinically meaningful differences in pharmacokinetics were observed in the clearance of avelumab based on mild or moderate hepatic impairment.  Caution should be exercised when avelumab is used in patients with severe hepatic impairment as there a...

**Adrenal Insufficiency** ğŸŸ¡ Moderate
- Avelumab can cause immune-mediated adrenal insufficiency.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensiv...

**Colitis** ğŸŸ¡ Moderate
- Immune-mediated colitis has been reported with the use of avelumab.  It is recommended to administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents followed by corticosteroid taper for moderate or severe or life-threatening coli...

**ç³–å°¿ç—… (Diabetes Mellitus)** ğŸŸ¡ Moderate
- Avelumab can cause type 1 diabetes mellitus.  Monitor for hyperglycemia or other signs and symptoms of diabetes.  Withhold treatment in cases of severe hyperglycemia until metabolic control is achieved.  Permanently discontinue avelumab for life-thre...

**Pneumonia** ğŸŸ¡ Moderate
- Immune-mediated pneumonitis, including fatal cases have been reported with the use of avelumab.  Monitor patients for signs with radiographic imaging and for symptoms of pneumonitis.  It is recommended to administer corticosteroids at a dose of 1 to ...

*å¦æœ‰ 2 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šHold**

**ç†ç”±ï¼š**
ç›®å‰åƒ…æœ‰æ¨¡å‹é æ¸¬æ”¯æŒï¼Œç¼ºä¹å¯¦éš›è‡¨åºŠè©¦é©—å’Œæ–‡ç»è­‰æ“šã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- è©³ç´°çš„è—¥ç‰©ä½œç”¨æ©Ÿè½‰è³‡æ–™ï¼ˆMOAï¼‰
- é€²ä¸€æ­¥çš„è‡¨åºŠè©¦é©—æ•¸æ“šä»¥æ”¯æŒå…¶åœ¨æ–°é©æ‡‰ç—‡ä¸­çš„æ‡‰ç”¨


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Sulfamerazine]({{ "/drugs/sulfamerazine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Povidone]({{ "/drugs/povidone/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Oxytetracycline]({{ "/drugs/oxytetracycline/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Vigabatrin]({{ "/drugs/vigabatrin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Trihexyphenidyl]({{ "/drugs/trihexyphenidyl/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Avelumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/avelumab/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_avelumab,
  title = {Avelumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/avelumab/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
